Bio-ReCell d.o.o.

Based in Slovenia, Bio-ReCell d. o. o. specializes in advanced cell therapy solutions, focusing on innovative products for cell separation and activation, serving clients in the biopharmaceutical and regenerative medicine sectors.

Bio-ReCell d. o. o. is a Slovenian company founded in 2018 and headquartered in Ljubljana.

The company focuses on providing biopharmaceutical solutions through advanced technologies in cell therapy. There are no noted changes in business strategy or operations since its inception. The founder's background details are not publicly available. The company has engaged in 1 deal, with Elements Capital Partners acquiring Bio-ReCell d.

o. o. for undisclosed financial terms, enhancing its business development efforts. Bio-ReCell specializes in advanced cell therapy solutions through innovative products designed for cell separation and activation.

Their core offerings include the Neptune™ system for CD3+ T-cell isolation, which effectively processes entire leukopaks while avoiding contamination from residual antibodies or particles. Additionally, they provide precision-engineered T-cell activation kits that offer unparalleled control and consistency during the activation process. The Revive™ system aims to streamline the isolation of therapeutic cells from adipose tissue, significantly enhancing regenerative medicine applications. Bio-ReCell's technologies are utilized primarily in the United States and Europe, serving a diverse client base that includes T-cell therapy manufacturers, regenerative medicine practitioners, and research institutions focused on cell and tissue therapies.

Bio-ReCell's revenue model is based on direct business-to-business transactions with clients in the biopharmaceutical and regenerative medicine sectors. The company engages in partnerships and collaborations, supplying their trademarked products such as Neptune™ and Revive™ to therapeutic manufacturers who utilize these technologies in their operations. Revenue generation occurs through sales of these proprietary systems, where clients typically purchase equipment and associated kits based on their production needs. Given the complex nature of cell therapy manufacturing, transactions are structured to include ongoing support and consultation, ensuring clients maximize the effectiveness of Bio-ReCell's solutions in their therapeutic applications.

Bio-ReCell plans to enhance its business development following its acquisition by Elements Capital Partners, focusing on designing and launching new products and technology enhancements. Specific timelines for product launches have not been disclosed. The company aims to expand its reach into new geographic markets, particularly within Europe and North America, to capitalize on the growing demand for cell therapy solutions. Recent funding will be allocated to support these initiatives, ensuring the company strengthens its market position and broadens its client base.